GSK lung cancer treatment data shows "positive anti-tumour activity"

GSK reported that its drug Ris-Rez showed a 61% response rate at 8mg/kg dose in a phase Ib study, higher than the 32% at 6mg/kg. The company plans to use the 8mg/kg dose in its ongoing phase III trial. GSK noted manageable side effects, with serious issues in 42% of higher-dose patients. The results will be presented at the ESMO 2026 congress. As of 0905 BST, GSK shares were up 0.16% at 1,865.50p.

GSK reported that its drug candidate, Risvutatug Rezetecan, showed a 61% response rate in a Phase 1b lung cancer trial, indicating positive anti-tumor activity according to the company.

GSK reported positive early data for Ris-Rez in treating extensive-stage small cell lung cancer. The phase Ib trial showed a 61% objective response rate at 8 mg/kg dose. GSK plans to present findings at ESMO Congress 2026. According to the company, the data supports ongoing development for this high-unmet-need indication.

GSK's risvutatug showed a 61% response rate at 8 mg/kg vs 32% at 6 mg/kg in a phase Ib SCLC trial. Adverse events were 42% at 8 mg/kg and 15% at 6 mg/kg. Full data is expected at ESMO 2026. GSK states the results support continued development.

GSK reported positive results from a drug trial for small cell lung cancer, with an 8mg/kg dose showing a 61% objective response rate. LondonMetric reported an 8% increase in net rental income to GBP240 million for the first half. Volex expects record half-year revenue of at least USD710 million, up 22% year-over-year, and annual profit at the upper end of market forecasts. ITM Power narrowed its annual loss to GBP24.8 million, with revenue up 68% to GBP43.6 million.

GSK reported a 61% response rate for its experimental lung cancer drug Ris-Rez in a phase Ib study, with 8 mg/kg dose showing higher efficacy but more severe side effects. The data, presented at ESMO Congress, support a global phase III trial. GSK aims for 40+ indications by 2040, though the results are not an immediate earnings driver.